Results 121 to 130 of about 14,094 (223)

Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis. [PDF]

Diabetes Care
Klein KR, Menacher A, Buse JB, Mann JFE, Tuttle KR, Kvist K, Andersen MR, Mayrdorfer M, Lingvay I.   +8 more
europepmc   +1 more source

Obesity in Classic Congenital Adrenal Hyperplasia: Mechanisms, Complications and Management

Clinical Endocrinology, EarlyView.
ABSTRACT Classic congenital adrenal hyperplasia (CCAH) is an autosomal recessive genetic disorder primarily caused by 21‐hydroxylase deficiency. Although the survival rate of patients has significantly improved with glucocorticoid replacement therapy, long‐term use of supraphysiological doses and multiple factors inherent to the disease itself have led
Jialin Mu, Yue Li, Meng Sun, Yulin Li, Panpan Li, Hui Zou   +5 more
wiley   +1 more source

15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss. [PDF]

Proc Natl Acad Sci U S A
Nalbandian M, Lone J, Le Moal E, Kim I, Jeuris K, Li YK, Kraft P, Zhao M, Koleckar K, Zhang Z, Svensson KJ, Blau HM.   +11 more
europepmc   +1 more source

The real‐world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real‐world practice in Canada. The study was conducted through an observational, retrospective, single‐arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada ...
Sean Wharton, Elham Kamran, Lehana Thabane, Peter Yin, Rebecca Christensen   +4 more
wiley   +1 more source

Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis. [PDF]

PLoS One
Chen Q, Chen T, Lin W, Chen X.
europepmc   +1 more source

Interventions for binge eating disorder in adults with type 2 diabetes: A systematic review

Diabetic Medicine, EarlyView.
Abstract Aims Binge eating disorder frequently co‐occurs with type 2 diabetes, creating a dual burden that may complicate both psychological well‐being and glycaemic management. Evidence on the effectiveness of health interventions in this population is limited.
Pernille Fiil Nybo, Nikolaj Vang Nielsen, Julie Drotner Mouritsen, Michael Einar Røder, Jakob Linnet   +4 more
wiley   +1 more source

Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system. [PDF]

J Manag Care Spec Pharm
Baalmann A, Michel J, Avedissian SN, Pow A, Farris K.   +4 more
europepmc   +1 more source

Semaglutide and the Retina

Journal of Diabetes
openaire   +3 more sources

Dual Glucagon and GLP‐1 Receptor Agonist Survodutide Improves Biomarkers of Beta‐Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This post hoc analysis evaluated the effect of survodutide on beta‐cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations. Materials and Methods Trial 1404‐0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks.
Elif I. Ekinci, Sandra González Maldonado, Anna Unseld, Jorge Arrubla Martinez, Anita M. Hennige, Corinna Schoelch   +5 more
wiley   +1 more source

Spinal Implant-Associated Infection in Type 2 and Type 1 Diabetes: Phenotype-Specific Inflammatory Features and Therapeutic Response to Semaglutide. [PDF]

JOR Spine
Olson TE, Lloyd TS, Hamad CD, Chun RF, Wiener J, Golzar A, Mehany J, Shahamatdar S, Kittredge A, Pearce L, Francis KP, Obeidin F, Holly LT, Yeaman MR, Adams JS, Bernthal NM, Sheppard WL.   +16 more
europepmc   +1 more source